Sagimet Biosciences suspends and terminates ATM prospectus supplement for Series A common stock effective Sept 30

Sagimet Biosciences Inc. suspended and terminated its at-the-market (ATM) prospectus supplement for Series A common stock effective Sept 30, according to a SEC filing.